Rule 1: The presence of functional groups such as aldehydes or ketones in a compound may increase its potential for causing adverse effects on the respiratory system. This rule can be applied to molecules represented by SMILES strings labeled as "1" in the given dataset. For example, the first molecule contains a carbonyl group (C=O) which could potentially contribute to this type of toxicity.
Rule 2: The presence of aromatic rings in a compound may also increase its potential for causing adverse effects on the respiratory system. This rule can be applied to molecules represented by SMILES strings labeled as "1" in the given dataset. For instance, the second molecule has two aromatic rings (C1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N) which could contribute to this type of toxicity.
Rule 3: The presence of charged groups such as ammonium ions (-NR3+) or carboxylate anions (-COO-) in a compound may decrease its potential for causing adverse effects on the respiratory system. This rule can be applied to molecules represented by SMILES strings labeled as "0" in the given dataset. For example, the last molecule has a negatively charged carboxylate anion (-COO-) which could reduce its ability to cross cell membranes and interact with biological targets.

================================

Rule 1: The presence of functional groups such as carboxylic acid or its derivatives, nitro compounds, amines, and halogenated hydrocarbons may increase the likelihood of causing adverse effects in the respiratory system.
Rule 2: The molecular weight and lipophilicity of the compound also play a role in determining its potential for adverse effects on the respiratory system. Compounds with high molecular weights and lipophilicities tend to accumulate in the lungs and may cause irritation or inflammation.
Rule 3: The shape and size of the molecule may also affect its ability to cross cell membranes and interact with biological targets. For example, molecules with linear shapes and small sizes may be more likely to penetrate the lung tissue and cause adverse effects compared to larger and more complex structures.

================================

Rule 1: If the molecular structure contains a naphthalene ring or a benzene ring attached to a sulfonamide group, it may have potential side effects on respiratory, thoracic and mediastinal disorders. The presence of these rings in the chemical structure indicates that they could be irritants or allergens for human tissues. Therefore, this rule suggests that such molecules should be carefully evaluated before being used as drugs.
Rule 2: If the molecular structure has a nitro group connected to a phenyl ring, it may also lead to adverse reactions associated with respiratory, thoracic and mediastinal disorders. This rule suggests that such compounds need careful evaluation during drug development process due to their potential toxicity.
Rule 3: If the molecular structure includes a carbonyl group bonded to two carbon atoms, it may potentially affect cardiovascular system. Such structures indicate that they might interfere with blood circulation and oxygen transport, leading to various health problems including heart attack and stroke. Therefore, this rule highlights the importance of evaluating the safety profile of such chemicals prior to using them as drugs.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If a molecule contains a sulfonyl group (SO2R) or a carbonyl group (COR) in its structure, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules represented by SMILES strings C1CS(=O)(=O)c2ccc(cc2)n1, CC(C)C(C(=O)OS(=O)(=O)C1SCC(C)C(C)C1)ON1CCOCC1, COC(=O)Nc1nc(C)s(C)sc1, CCCOc1ccccc1SSc1nncn1, O=C(Cn1nc(C)s(C)Sc1)NNC(=O)C1=CC=CC=C1, OC(=O)C(C)(C)C(C(=O)OP(=O)(OC2OCCO2)OC2OCCO2)(C)C, c1ccc(cc1Br)C(C)(C)C(=O)NCCSNa+, CN(C)C(=O)C(C)(C)C(=O)OCCOCP(=O)(OC1OCCO1)OC1OCCO1, CNC(=O)C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to molecules represented by SMILES strings C1CNN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl, CC(CC1=CC=CC=C1)N, N(=O)[O-], CNCCNCCN, CCC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C, CCS(C)(=O)C(C(=O)O)NS(=O)(=O)C1=CC=C(C=C1)C, COC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N, CCN(C)CC(C1=CC(=C(C=C1)O)O)O, CNC(C)(COC(=O)N)COC(=O)N, NCCCCCCCC1=CC=C(C=C1)CCC(

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If a molecule contains a phosphorus atom bonded to four oxygen atoms in a cyclic structure, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. The first two molecules in the dataset meet this criterion and have labels of 1, indicating they do have the potential to cause these disorders.
Rule 2: If a molecule contains a fluorine atom attached to a carbon atom in a polycyclic ring system, then it may also have the potential to cause respiratory, thoracic and mediastinal disorders. The third molecule in the dataset meets this criterion and has a label of 1, indicating it does have the potential to cause these disorders.
Rule 3: If a molecule contains a gadolinium ion or a sodium ion, then it may also have the potential to cause respiratory, thoracic and mediastinal disorders. However, since only one molecule in the dataset contains either of these ions, we cannot make any definitive conclusions about their relationship to these disorders without more data.

================================

Rule 1: The presence of functional groups such as sulfonyl (-SO2-) or carbonyl (-C=O) in a compound may increase its potential for causing respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings CS(=O)C 0 and CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3C2C(CC4=CC(=O)C=CC34C)Cl)O)C)C)OC(=O)CC 0.
Rule 2: Compounds containing negatively charged ions like phosphate (-PO4^2-) or carboxylate (-COO-) may have higher chances of causing respiratory, thoracic and mediastinal disorders due to their ability to cross cell membranes more easily than neutral molecules. This rule applies to compounds C(CN)C(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+] 1 and CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F 1.
Rule 3: Molecules with aromatic rings and conjugated double bonds may also be associated with increased risk of respiratory, thoracic and mediastinal disorders. This rule applies to compounds C1=NNC2=C1C(=

================================

Rule 1: If the molecular structure contains a functional group such as carbonyl or carboxyl groups, it may lead to respiratory, thoracic and mediastinal disorders if present in high concentrations. The presence of these groups can irritate the lungs and cause inflammation.
Rule 2: If the molecular structure contains halogen atoms such as chlorine or fluorine, it may increase the likelihood of causing adverse effects on the respiratory system. These atoms can disrupt the normal function of cells and tissues by reacting with proteins and enzymes.
Rule 3: If the molecular structure contains aromatic rings or conjugated double bonds, it may also increase the risk of adverse effects on the respiratory system due to their ability to absorb UV radiation and form free radicals. This can damage DNA and other cellular components leading to various health problems including cancer.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If a molecule contains a sulfonyl group (SO2R) or a carbonyl group (COR) in its structure, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules represented by SMILES strings C1CS(=O)(=O)c2ccc(cc2)n1, CC(C)C(C(=O)OS(=O)(=O)C1SCC(C)C(C)C1)ON1CCOCC1, COC(=O)Nc1nc(C)s(C)sc1, CCCOc1ccccc1SSc1nncn1, O=C(Cn1nc(C)s(C)Sc1)NNC(=O)C1=CC=CC=C1, OC(=O)C(C)(C)C(C(=O)OP(=O)(OC2OCCO2)OC2OCCO2)(C)C, c1ccc(cc1Br)C(C)(C)C(=O)NCCSNa+, CN(C)C(=O)C(C)(C)C(=O)OCCOCP(=O)(OC1OCCO1)OC1OCCO1, CNC(=O)C

================================

Rule 1: If a compound contains a functional group such as carbonyl or carboxylic acid, it may have potential side effects on respiratory, thoracic and mediastinal organs. This rule can be applied to compounds labeled as 1 in the given dataset. For example, the first compound has a carbonyl group which could potentially affect these organs.
Rule 2: Compounds containing nitrogen atoms in their structure may also exhibit similar side effects if they are present in a conjugated system. The second compound in the dataset has a conjugated system involving two nitrogen atoms, making it more likely to cause adverse reactions.
Rule 3: A compound's solubility in water may play a role in its ability to cause adverse effects. Hydrophilic compounds tend to dissolve easily in water and may be more likely to interact with biological systems than hydrophobic ones. Therefore, compounds labeled as 1 in the dataset may contain hydrophilic groups such as hydroxyl or amine groups. However, this rule should be used cautiously since other factors such as molecular size and shape also influence toxicity.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders based on its structure:
Rule 1: If the molecule contains a benzene ring or a similar aromatic system, it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. The presence of such a system in a molecule can increase its lipophilicity, which can lead to increased absorption into the body and potentially harmful interactions with biological systems.
Rule 2: If the molecule contains a carbonyl group (C=O), it may also have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. Carbonyl groups can act as hydrogen bond acceptors, which can affect the solubility and reactivity of the molecule. They can also contribute to the overall polarity of the molecule, which can impact its ability to cross cell membranes and interact with other molecules within cells.
Rule 3: If the molecule contains a halogen atom (such as chlorine or fluorine), it may also have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. Halogen atoms can alter the electronic properties of the molecule, which can impact its chemical behavior and potential for interaction with biological systems. Additionally, they can increase the hydrophobicity of the molecule, which can enhance its ability to penetrate cell membranes and potentially cause harm.

================================

Rule 1: If the molecular structure contains a naphthalene ring or a benzene ring attached to a sulfonamide group, it may have potential side effects on respiratory, thoracic and mediastinal disorders. The presence of these rings in the chemical structure indicates that they could be irritants or allergens for human tissues. Therefore, this rule suggests that such molecules should be carefully evaluated before being used as drugs.
Rule 2: If the molecular structure has a nitro group connected to a phenyl ring, it may also lead to adverse reactions associated with respiratory, thoracic and mediastinal disorders. This rule suggests that such compounds need careful evaluation during drug development process due to their potential toxicity.
Rule 3: If the molecular structure includes a carbonyl group bonded to two carbon atoms, it may potentially affect cardiovascular system. Such structures indicate that they might interfere with blood circulation and oxygen transport, leading to various health problems including heart attack and stroke. Therefore, this rule highlights the importance of evaluating the safety profile of such chemicals prior to using them as drugs.

================================

Rule 1: If a compound contains a functional group such as carbonyl or carboxylic acid, it may have potential side effects on respiratory, thoracic and mediastinal organs. This rule can be applied to compounds labeled as 1 in the given dataset. For example, the first compound has a carbonyl group which could potentially affect these organs.
Rule 2: Compounds containing nitrogen atoms in their structure may also exhibit similar side effects if they are present in a conjugated system. The second compound in the dataset has a conjugated system involving two nitrogen atoms, making it more likely to cause adverse reactions.
Rule 3: A compound's solubility in water may play a role in its ability to cause adverse effects. Hydrophilic compounds tend to dissolve easily in water and may be more likely to interact with biological systems than hydrophobic ones. Therefore, compounds labeled as 1 in the dataset may contain hydrophilic groups such as hydroxyl or amine groups. However, this rule should be used cautiously since other factors such as molecular size and shape also influence toxicity.

================================

Rule 1: If there is a presence of functional groups such as nitro group or halogen group in the structure of the molecule, then it may lead to adverse effects on respiratory, thoracic and mediastinal disorders. The given SMILES strings with labels 1 have these functional groups present in their structures.
Rule 2: If the molecular weight of the compound is greater than 500 Daltons, then it may also lead to adverse effects on respiratory, thoracic and mediastinal disorders. The given SMILES string with label 1 has a molecular weight of 656 Da which satisfies this rule.
Rule 3: If the molecule contains a benzene ring or other aromatic rings, then it may increase the risk of adverse effects on respiratory, thoracic and mediastinal disorders due to its lipophilic nature. However, this rule cannot be generalized as some molecules containing aromatic rings do not show any adverse effects. The given SMILES string with label 0 does not contain any aromatic rings but still shows no adverse effects.

================================

Rule 1: If there is a presence of functional group like "-COOH" or "-SO3H" in the structure of a molecule, then it may lead to adverse effects on respiratory system.
Rule 2: If there is a presence of aromatic ring in the structure of a molecule, then it may also lead to adverse effects on respiratory system.
Rule 3: If there is a presence of halogen atom like chlorine or fluorine in the structure of a molecule, then it may increase the lipophilicity of the compound which leads to increased absorption through skin and hence increases the chances of causing adverse effects on respiratory system.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If a molecule contains a sulfonyl group (SO2R) or a carbonyl group (COR) in its structure, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules represented by SMILES strings C1CS(=O)(=O)c2ccc(cc2)n1, CC(C)C(C(=O)OS(=O)(=O)C1SCC(C)C(C)C1)ON1CCOCC1, COC(=O)Nc1nc(C)s(C)sc1, CCCOc1ccccc1SSc1nncn1, O=C(Cn1nc(C)s(C)Sc1)NNC(=O)C1=CC=CC=C1, OC(=O)C(C)(C)C(C(=O)OP(=O)(OC2OCCO2)OC2OCCO2)(C)C, c1ccc(cc1Br)C(C)(C)C(=O)NCCSNa+, CN(C)C(=O)C(C)(C)C(=O)OCCOCP(=O)(OC1OCCO1)OC1OCCO1, CNC(=O)C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects related to respiratory, thoracic and mediastinal disorders:
Rule 1: If a molecule contains a metal ion such as Ga+3 or K+, it may have the potential to cause adverse effects related to respiratory, thoracic and mediastinal disorders.
Explanation: The presence of these ions in a molecule could potentially affect its chemical and physical properties, leading to interactions with biological systems and potentially causing harm. However, this rule should be taken with caution since there may be other factors at play that contribute to the observed toxicity.
Rule 2: If a molecule contains a functional group such as CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C or CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C, it may have the potential to cause adverse effects related to respiratory, thoracic and mediastinal disorders.
Explanation: These functional groups contain elements that are known to be toxic or carcinogenic, which could potentially lead to adverse health effects when present in a molecule. Again, this rule should be considered preliminary until further research is conducted.
Rule 3: If a molecule contains a sulfonic acid group (-SO3H), it may not have the potential to cause adverse effects related to respiratory, thoracic and mediastinal disorders.
Explanation: Sulfonic acid groups are often used in drug design due to their ability to increase water solubility and improve absorption into the body. While they may not necessarily prevent a molecule from causing adverse effects, they do provide some level of safety margin.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If a molecule contains a sulfonyl group (SO2R) or a carbonyl group (COR) in its structure, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules represented by SMILES strings C1CS(=O)(=O)c2ccc(cc2)n1, CC(C)C(C(=O)OS(=O)(=O)C1SCC(C)C(C)C1)ON1CCOCC1, COC(=O)Nc1nc(C)s(C)sc1, CCCOc1ccccc1SSc1nncn1, O=C(Cn1nc(C)s(C)Sc1)NNC(=O)C1=CC=CC=C1, OC(=O)C(C)(C)C(C(=O)OP(=O)(OC2OCCO2)OC2OCCO2)(C)C, c1ccc(cc1Br)C(C)(C)C(=O)NCCSNa+, CN(C)C(=O)C(C)(C)C(=O)OCCOCP(=O)(OC1OCCO1)OC1OCCO1, CNC(=O)C

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders:
Rule 1: If the molecule contains a benzene ring (represented by the SMILES string C1=CC=C(C=C1)), then it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to molecules represented by the first two SMILES strings in the dataset.
Rule 2: If the molecule contains a sulfonyl group (represented by the SMILES string C(C(C(=O)O)S)(C(=O)O)S), then it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to one molecule represented by the third SMILES string in the dataset.
Rule 3: If the molecule contains a fluorine atom (represented by the SMILES string F), then it may not have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to one molecule represented by the sixth SMILES string in the dataset.
It's important to note that these rules are based solely on the information provided in the given dataset and should be used as a starting point for further analysis rather than definitive conclusions.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders:
Rule 1: If the molecule contains a benzene ring (represented by the SMILES string C1=CC=C(C=C1)), then it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to molecules represented by the first two SMILES strings in the dataset.
Rule 2: If the molecule contains a sulfonyl group (represented by the SMILES string C(C(C(=O)O)S)(C(=O)O)S), then it may have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to one molecule represented by the third SMILES string in the dataset.
Rule 3: If the molecule contains a fluorine atom (represented by the SMILES string F), then it may not have the potential to cause adverse effects related to respiratory, thoracic, and mediastinal disorders. This rule applies to one molecule represented by the sixth SMILES string in the dataset.
It's important to note that these rules are based solely on the information provided in the given dataset and should be used as a starting point for further analysis rather than definitive conclusions.

================================

Rule 1: The presence of a sulfonamide group in a compound increases its likelihood of causing respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings starting with "SO2NH" or "SNH". For example, the first compound listed has this functional group and is labeled as having a side-effect activity related to these disorders. On the other hand, the second compound does not have this group and is labeled as not having such an activity.
Rule 2: A compound containing a nitro group attached to an aromatic ring may be more likely to cause respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings starting with "C1=CC=C(C=C1)NO2" or "C1=NN=C(C=C1)O2". For instance, the third compound listed has this functional group and is labeled as having a side-effect activity related to these disorders. However, the fourth compound does not have this group but still causes similar effects due to another structural feature.
Rule 3: A compound with a carboxylic acid group conjugated to an alkene may be less likely to cause respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings ending with "Cc1ccc(cc1)Oc2ccccc2COOH" or "Cc1ccc(cc1)Nc2ccccc2CONHC(=O)C". For example, the fifth compound listed has this structure and is labeled as not

================================

Rule 1: The presence of functional groups such as carboxylic acid or its derivatives, aldehydes, ketones, esters, amides, etc. in a compound may increase the likelihood of causing respiratory, thoracic and mediastinal disorders.
Rule 2: A compound containing aromatic rings or conjugated double bonds may also have a higher risk of causing these types of adverse effects.
Rule 3: The molecular weight and lipophilicity of a compound may also play a role in determining its potential to cause respiratory, thoracic and mediastinal disorders. Compounds with lower molecular weights and greater hydrophilicity may be less likely to cross cell membranes and enter the bloodstream, reducing their ability to cause systemic toxicity.

================================

Rule 1: If there is a presence of any functional group such as "-COOH" or "-SO3H" in the molecular structure, then it may lead to adverse effects on the respiratory system.
Rule 2: If there is a presence of any aromatic ring in the molecular structure, then it may lead to adverse effects on the thoracic and mediastinal disorders.
Rule 3: If there is a presence of any halogen atom like chlorine or fluorine in the molecular structure, then it may lead to adverse effects on the cardiovascular system.

================================

Rule 1: If the molecular structure contains a naphthalene ring or a benzene ring attached to a sulfonamide group, it may have potential side effects on respiratory, thoracic and mediastinal disorders. The presence of these rings in the chemical structure indicates that they could be irritants or allergens for human tissues. Therefore, this rule suggests that such molecules should be carefully evaluated before being used as drugs.
Rule 2: If the molecular structure has a nitro group connected to a phenyl ring, it may also lead to adverse reactions associated with respiratory, thoracic and mediastinal disorders. This rule suggests that such compounds need careful evaluation during drug development process due to their potential toxicity.
Rule 3: If the molecular structure includes a carbonyl group bonded to two carbon atoms, it may potentially affect cardiovascular system. Such structures indicate that they might interfere with blood circulation and oxygen transport, leading to various health problems including heart attack and stroke. Therefore, this rule highlights the importance of evaluating the safety profile of such chemicals prior to using them as drugs.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If the molecule contains a chlorine atom bonded to a carbon atom, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules numbered 1, 7, 8, 9, 10, 11, 12, 13, 14 in the dataset.
Rule 2: If the molecule contains a nitro group (-NO2) attached to an aromatic ring, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules numbered 2, 3, 4, 5, 6 in the dataset.
Rule 3: If the molecule contains a sulfonamide group (-SO2NH2) or a urea group (-CONH2), then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules numbered 15, 16 respectively in the dataset.

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 in the dataset.
Rule 2: If the molecule contains a benzene ring attached to a carbonyl group (-C=O) through a single bond, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 in the dataset.
Rule 3: If the molecule contains a chlorine atom (-Cl) bonded to a carbon atom, then it may have the potential to cause

================================

Rule 1: The presence of a sulfonamide group in a compound increases its likelihood of causing respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings starting with "SO2NH" or "SNH". For example, the first compound listed has this functional group and is labeled as having a side-effect activity related to these disorders. On the other hand, the second compound does not have this group and is labeled as not having such an activity.
Rule 2: A compound containing a nitro group attached to an aromatic ring may be more likely to cause respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings starting with "C1=CC=C(C=C1)NO2" or "C1=NN=C(C=C1)O2". For instance, the third compound listed has this functional group and is labeled as having a side-effect activity related to these disorders. However, the fourth compound does not have this group but still causes similar effects due to another structural feature.
Rule 3: A compound with a carboxylic acid group conjugated to an alkene may be less likely to cause respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings ending with "Cc1ccc(cc1)Oc2ccccc2COOH" or "Cc1ccc(cc1)Nc2ccccc2CONHC(=O)C". For example, the fifth compound listed has this structure and is labeled as not

================================

Rule 1: If a compound contains a functional group such as "-COOH" or "-OH", it may have potential for causing adverse effects on respiratory, thoracic and mediastinal disorders. This rule can be applied to compounds in rows 1, 6, 7, and 9 of the given dataset.
Rule 2: If a compound has a long carbon chain structure, it may also have potential for causing adverse effects on these organs. This rule can be applied to row 8 of the dataset.
Rule 3: If a compound contains a nitro group (-NO2), it may not have any significant impact on respiratory, thoracic and mediastinal disorders. This rule can be applied to row 3 of the dataset.

================================

Rule 1: The presence of functional groups such as sulfonyl (-SO2-) or carbonyl (-C=O) in a compound may increase its potential for causing respiratory, thoracic and mediastinal disorders. This rule applies to compounds represented by SMILES strings CS(=O)C 0 and CCC(=O)OCC(=O)C1(C(CC2C1(CC(C3C2C(CC4=CC(=O)C=CC34C)Cl)O)C)C)OC(=O)CC 0.
Rule 2: Compounds containing negatively charged ions like phosphate (-PO4^2-) or carboxylate (-COO-) may have higher chances of causing respiratory, thoracic and mediastinal disorders due to their ability to cross cell membranes more easily than neutral molecules. This rule applies to compounds C(CN)C(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+] 1 and CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F 1.
Rule 3: Molecules with aromatic rings and conjugated double bonds may also be associated with increased risk of respiratory, thoracic and mediastinal disorders. This rule applies to compounds C1=NNC2=C1C(=

================================

Based on the given dataset, here are three rules that could be used to predict if a molecule has the potential to cause respiratory, thoracic and mediastinal disorders based on its structure:
Rule 1: If the molecule contains a sulfonamide group (-SO2NH-) or a nitro group (-NO2), then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 in the dataset.
Rule 2: If the molecule contains a benzene ring attached to a carbonyl group (-C=O) through a single bond, then it may have the potential to cause respiratory, thoracic and mediastinal disorders. This rule applies to molecules 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 in the dataset.
Rule 3: If the molecule contains a chlorine atom (-Cl) bonded to a carbon atom, then it may have the potential to cause

================================

